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Safety of efavirenz in ﬁrst-trimester of pregnancy:
a systematic review and meta-analysis of outcomes
from observational cohorts
Nathan Ford
a,b, Lynne Mofenson
c, Katharina Kranzer
d, Lanre Medu
e,
Lisa Frigati
f, Edward J Mills
g and Alexandra Calmy
h
Introduction: Data on efavirenz safety in ﬁrst trimester pregnancy are conﬂicting. We
conducted a systematic review and meta-analysis of the available evidence from
observational cohorts.
Methods: We ran duplicate searches of databases (up to 02 January, 2010) and
searchable websites of major HIV conferences (up to February, 2010) to identify
observational cohorts reporting birth outcomes among women exposed to efavirenz
during the ﬁrst trimester of pregnancy. Our primary endpoint was birth defects of any
kind; secondary outcomes were spontaneous abortions, termination of pregnancy,
stillbirths, and preterm delivery.
Results: Sixteen studies met our inclusion criteria, comprising 11 prospective cohorts
and ﬁve retrospective reviews. Nine prospective studies reported on rates for birth
defectsbothamongwomenexposedtoefavirenz-containingregimens(1132livebirths)
and non-efavirenz-containing regimens (7163 live births) during ﬁrst trimester, giving a
pooled, nonsigniﬁcant relative risk of 0.87 [95% conﬁdence interval (CI) 0.61–1.24%,
P¼0.45]. Low heterogeneity was observed between studies (I
2¼0, 95% CI 0–56.3%,
P¼0.85). Across all studies (1256 live births), one neural tube defect (meningomye-
locele) was observed with ﬁrst trimester efavirenz exposure, giving a prevalence of
0.08% (95% CI 0.002–0.44%).
Conclusion: We found no increased risk of overall birth defects among women
exposed to efavirenz during the ﬁrst trimester of pregnancy compared with exposure
to other antiretroviral drugs. Prevalence of overall birth defects with ﬁrst trimester
efavirenz exposure was similar to the ranges reported in the general population.
However, the limited sample size for detection of rare outcomes such as neural tube
defects prevents a deﬁnitive conclusion.
 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2010, 24:000–000
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Introduction
Current guidelines for the use of antiretroviral therapy
(ART) during pregnancy recommend that women be
offered the same drugs that are prescribed to nonpregnant
HIV-infected individuals. The exception is efavirenz,
which has been associated with a potential increase in the
risk of central nervous system birth defects. Initial reports
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from animal studies led to a classiﬁcation of efavirenz as a
Class C drug (‘risk cannot be ruled out’) by the United
States Food and Drug Administration (FDA); in
cynomolgus monkeys treated with efavirenz at a dose
resulting inplasmaconcentrationscomparabletosystemic
human therapeutic exposure, signiﬁcant central nervous
system defects (anencephaly, microphthalmia and
anophthalmia, and cleft palate) were observed in three
of 20 infant monkeys. Subsequent retrospective case
reports of several human infants with ﬁrst trimester
exposure to efavirenz who were born with neural tube
defects (myelomeningocele) [1,2], led the FDA to
reclassify efavirenz as a Class D drug (‘evidence of human
fetal risk’) in 2005 and recommend against its use during
ﬁrst trimester pregnancy [3].
Prospective reports from the Antiretroviral Pregnancy
Registry [4] and cohort studies [5] have found no
evidence of an increased incidence of overall congenital
abnormalities among infants born to pregnant women
who received efavirenz in the ﬁrst trimester compared
with rates among the general population. However, the
relatively small sample size of these cohorts provides
insufﬁcient power to rule out an increased risk of a
speciﬁc and rare congenital abnormality such as a neural
tube defect. The latest WHO guidelines for resource-
limited settings acknowledge the low quality of evidence
but recommend against using efavirenz in ﬁrst-trimester
given the potential seriousness of the adverse event (but
also do note that use after the ﬁrst trimester can be
considered) [6]. The United States guidelines issued in
April 2009 recommend avoidance of efavirenz in the ﬁrst
trimester of pregnancy but note that use after the ﬁrst
trimester can be considered if it is the best choice in
individual cases, and that if it is continued postpartum
adequate contraception must be assured [7]. European
guidelines issued at the end of 2009 recommend against
using efavirenz in pregnancy altogether [8]. These safety
concerns have led to a decline in efavirenz use in
pregnancy in developed countries. One study from
Europe found that although approximately 10% of
women were reported to be receiving efavirenz at the
time of conception, virtually all had switched by the third
trimester [9]. This move away from efavirenz use during
pregnancy in developed countries is facilitated by the
availability of a wide drug formulary and widespread
access to prenatal care [10].
In developing countries, ART options are far more
limited. Current WHO guidelines for resource-limited
settings recommend efavirenz or nevirapine as core ﬁrst-
line drugs [6], and around one-ﬁfth of people on ART in
resource-limited countries are receiving an efavirenz-
based regimen. In South Africa, efavirenz is prescribed
more frequently than nevirapine [11]. Efavirenz is widely
used because it is relatively well tolerated (psychiatric
symptoms being the predominant toxicity, with rash and
hepatic toxicity less frequent than seen with nevirapine),
easy to monitor, and shows similar virological suppression
compared with nevirapine [12]. Efavirenz is one of the
antiretrovirals of choice for patients coinfected with
tuberculosis because it has fewer interactions with
rifampicin compared with nevirapine [13]. In addition,
as emerging evidence increasingly supports a move
towards earlier initiation of antiretroviral therapy [6], use
of efavirenz in women of childbearing age will likely
increase, given the risk of hypersensitivity reactions
associated with nevirapine use at higher CD4 cell counts.
This is of particular relevance to pregnant women, who
are generally diagnosed earlier in their disease than the
general population.
These issues, together with the practical constraints
associated with regimen changes in large treatment
programmes with limited resources, call for an assessment
of the evidence regarding the safety of efavirenz in
pregnancy.Weconductedasystematicreviewtoassessthe
available evidence from observational cohorts on
efavirenz safety in ﬁrst-trimester pregnancy.
Methods
Search strategy
We developed a highly sensitive search strategy combin-
ing key terms that may indicate birth defects (e.g.
anencephaly, myelomeningocele, microophthalmia,
anophthalmia, cleft palate, neural tube defect, birth
defect, abnormality) with the MeSH headings ‘HIV’ or
‘AIDS’. Initial searches were developed (N.F.) for the
following databases from inception to 02 January, 2010):
MEDLINE via PubMed, EMBASE, Cochrane CEN-
TRAL, CINAHL, PsycInfo, LILACS, Current Con-
trolled Trials (www.controlled-trials.com) and the Uni-
ted States National Institutes of Health
(www.clinicaltrials.gov); and the searchable websites of
major HIV conferences: all International AIDS Society
conferences (up to Cape Town, July 2009) and all
Conferences on Retroviruses and Opportunitistic Infec-
tions (up to San Francisco, February 2010). We also
searched the Antiretroviral Pregnancy Registry (http://
www.apregistry.com). Our search was complemented by
reviewing bibliographies of relevant papers and contact-
ing individual clinical researchers and large treatment
cohorts: the Antiretroviral Treatment in Lower Income
Countries (ART-LINC) Collaboration, the Antiretro-
viral Cohort Collaboration (ART-CC), the European
Collaborative Study (ECS), the International epidemio-
logic Databases to Evaluate AIDS Southern Africa
(IeDEA-SA), Me ´decins Sans Frontie `res, the MTCT Plus
Initiative, the National Institute of Child Health and
Human Development International Site Development
Initiative (NISDI), the Paediatric European Network for
Treatment of AIDS (PENTA), the Perinatal Health
Research Unit (PHRU) and the Reproductive Health
Research Unit (RHRU).
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Study selection
Oneofus(N.F.)didapreliminarysearchscanningalltitles
for eligibility according to predeﬁned inclusion criteria.
Afterobtainingfullabstractsfor potentiallyeligiblestudies
two reviewers (N.F., K.K.) worked independently to
assess eligibility. Once all potentially relevant full-text
articles and abstracts were identiﬁed, we consulted as a
team (N.F., K.K., L.M.) to achieve consensus regarding
eligibility.
Data extraction
Data extraction was conducted independently, in
duplicate, using a standardized form (N.F., K.K.), and
once tabulated was subsequently veriﬁed by a third
investigator (L.M.). Data abstractors collected infor-
mation about the study setting, study populations, sample
size, duration of exposure, and birth outcomes. Our
primaryendpointwasbirthdefectsof anykind;secondary
outcomes were spontaneous abortions, termination of
pregnancy, stillbirths, and preterm delivery. We sought to
compare the risk of birth defects among infants born to
women receiving efavirenz during the ﬁrst trimester of
pregnancy with the risk associated with exposure to other
antiretrovirals also in the ﬁrst trimester. Unsystematic
observations (case series or case reports) were excluded
from all analyses.WeappliedtheGRADE system toassess
the quality of evidence [14].
Data analysis
In order to assess interrater reliability on inclusion of
articles, we calculated the f statistic, which provides a
measure of interobserver agreement independent of
chance [15]. N.F. and E.M. conducted all statistical
analyses. We calculated the relative risk (RR) and 95%
conﬁdence intervals (95% CI) of the primary outcomes
within cohorts by comparing birth defects in infants
exposed to efavirenz during the ﬁrst trimester vs. infants
exposed to other antiretroviral drugs, according to the
number of events reported in the original studies.
Spontaneous and induced abortions and stillbirths were
excluded from the denominator of birth defects,
consistent with reporting norms. We pooled data using
the DerSimonian-Laird random effects method, which
recognizes and anchors studies as a sample of all potential
studies, and incorporates an additional between-study
componenttotheestimateofvariability[16].Intheevent
of zero outcome events in one arm, we prepared to apply
the Haldane method and add 0.5 to each arm [17]. We
calculated the I
2 statistic for each analysis as a measure of
the proportion of the overall variation that is attributable
to between-study heterogeneity, and calculated the
appropriate I
2 conﬁdence intervals. We conducted
univariate sensitivity analysis assessing study location,
duration of exposure, and status of publication. Preva-
lence rates were calculated for secondary outcomes. All
P-values are two-sided. We considered a P-value less than
0.05 to be signiﬁcant. Analyses were conducted using
StatsDirect (version 2.5.2, www.statsdirect.com), Stata
(version 11, www.stata.com), and GRADE Pro (www.
gradeworkinggroup.org).
Results
Figure 1 shows the ﬂow diagram of study selection for
analysis. Ninety studies passed the ﬁrst screening of
articles from titles and abstracts; agreement between
reviewers on inclusion of abstracts for further analysis was
strong (f¼0.87). A further eight studies were included
from article bibliographies and conference abstracts, and
72 were excluded because they did not meet our
inclusion criteria. Of the remaining 26 studies considered
eligible for inclusion, two studies were excluded because
datawerenotdisaggregatedbytrimesterandauthorswere
unable to provide clariﬁcation [18,19], and three did not
have outcome data available; additional data on secondary
outcomes from one unpublished cohort (MTCT-Plus,
communication with Dr Elaine Abrams March 5 2010)
wereincluded.Ofthe21studiesthatremainedeligiblefor
inclusion, three unsystematic retrospective reports ident-
iﬁed at initial screening, including one case series [2] and
two case reports [1,20], were excluded from analysis.
Individual studies were cross-checked against the Anti-
retroviral Pregnancy Registry to avoid duplicate report-
ing and two studies were excluded from analysis for this
reason [21,22]. Overall, 16 studies were included for
analysis (Table 1), including 11 prospective cohorts
(including the MTCT-Plus cohort) [4,5,11,23–29], and
ﬁve retrospective cohorts [30–34]. Nine studies were
done in resource-limited settings (South Africa [11,29–
31], Botswana [23], Ivory Coast [24], Brazil [26,32] and
one multisite study: the MTCT-Plus Initiative), six in
Europe [5,25,27,28,33,34] and one primarily in the
United States [4]. Eight were journal articles
[5,11,23,25,26,28,31,34], six were conference abstracts
[24,27,29,30,32,33], one was an unpublished cohort
(MTCT Plus), and one was the Antiretroviral Pregnancy
Registry report [4]. (Table 1) Two studies were published
inFrench[24,34]andtheremainder publishedinEnglish.
Additional data on secondary outcomes from one study
[32] were reported in a separate abstract [35]. Authors
provided additional birth outcome data for six studies and
the MTCT-Plus cohort [5,11,24,26,28,31].
Birthdefectsamong infantsborn towomenwhoreceived
efavirenz in the ﬁrst trimester in the 14 studies with
reports of defects by trimester of exposure are summar-
ized in Table 2. (Autopsy reports of birth defects from
abortuses were reported by two studies [11,34] but these
are not included as reporting across cohorts was
inconsistent). Overall, nine of the prospective studies
[4,5,11,23–28]reportedonratesforbirthdefectsforboth
infants born to women receiving efavirenz-containing
regimens (35 defects in 1132 women with live births) and
non-efavirenz-containing regimens (289 defects in 7163
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women with live births) during ﬁrst trimester, giving a
pooled,nonsigniﬁcantrelativeriskof0.87(95%CI0.61–
1.24%, P¼0.45) (Fig. 2); low heterogeneity was
observed between studies (I
2¼0, 95% CI 0–56.3%,
P¼0.85). Studies conducted in developed-country
settings did not differ signiﬁcantly compared with those
in resource-limited settings (P¼0.46); studies in which
exposure was limited to ﬁrst trimester did not differ from
studies where mean exposure was longer (P¼0.78);
outcomes from journal publications and the public
Antiretroviral Pregnancy Registry did not differ from
outcomes reported as abstracts (P¼0.50).
Incidence of overall birth defects among infants born to
women who received efavirenz in the ﬁrst trimester was
2.9% (95% CI 2.1–4.0%) and ranged from 0% [32] to
22.6% (95% CI 9.6–41.1%) [27]. Across all cohorts with
birth defect data (1256 women with live births), one
infant with a neural tube defect (myelomeningocele) was
observed, giving an incidence proportion of 0.08% (95%
CI 0.002–0.44%). (Table 2) An additional case of
anophthalmia with severe oblique facial clefts and
amniotic banding of the arm was reported with ﬁrst
trimester efavirenz exposure (4). Four prospective studies
reported data for both ﬁrst trimester (31 defects in 920
live births) and second/third trimester efavirenz exposure
(19 defects in 695 live births) [4,5,11,27]; there was no
difference in the pooled relative risk between these
groups (RR¼0.91, 95% CI¼0.46–1.79%, P¼0.79).
Secondary outcomes were reported variously across
studies (Fig. 3). Seven studies reported spontaneous
abortions in women with ﬁrst trimester efavirenz
exposure (39 abortuses in 628 pregnancies) [11,24,28–
30,34,35] with prevalence rates ranging from 2.6% (95%
CI0.1–13.5%)to16.7%(95%CI2.1–48.4%).Sixstudies
and one unpublished cohort (MTCT-Plus) reported on
rates of stillbirths (24 stillbirths in 715 pregnancies)
[5,11,23,24,28,30],with ratesrangingfrom 0(95%CI 0–
9.3%) to 13% (95% CI 1.7–40.4%). Five studies reported
on preterm deliveries (55 preterm deliveries in 399 live
births) [5,23,24,26,28], with rates ranging from 9.1%
(95% CI 1.1–29.1%) to 18.2% (95% CI 7.0–35.5%).
Rates of termination of pregnancy, reported by ﬁve
4 AIDS 2010, Vol 24 No 00
90 full text studies reviewed
26 studies considered eligible 
for inclusion 
1098 studies screened by title 
and abstract
21 studies eligible for inclusion 
1008 studies excluded
(not relevant)
5 studies excluded
Data not disaggregated by 
trimester (2)
Outcome data not available (3)
72 studies excluded
19 reviews or commentaries
9 duplicate reports
44 Not relevant
8 additional studies
identified through 
bibliographies
16 studies included in final 
analysis
6 studiesexcluded
Unsystematic observational 
studies (3)
Data also reported in 
Antiretroviral Pregnancy Registry  
(3)
Data reported from one 
unpublished cohort (MTCT-
Plus) included
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prospective studies [11,21,22,26,28], three retrospective
reviews [30,31,34] and one unpublished cohort (MTCT-
Plus) (81 terminations in 688 pregnancies), ranged from
2.5% (95% CI 0.8–5.7%) to 33.7% (95% CI 23.7–
44.9%). One of these studies reported a relative risk of
termination 5.73 times higher (95% CI 1.45- 22.75%;
P¼0.0017) among women exposed to efavirenz
compared with other antiretroviral drugs; termination
requests were based on verbal information alone (i.e.,
decisions were not based on ultrasound scans) [30].
Our GRADE assessment rated the quality of studies as
being low. The main limitations were that the majorityof
studies failed to consider potential threats to validity; ﬁve
studies considered sources of bias and only three studies
adjustedfor potentialconfounders. Moststudieswerealso
limited by a small sample size and low event rate that
resulted in low statistical conﬁdence around the point
estimate.
Discussion
The recommendation against using efavirenz in preg-
nancy is largely based on neural tube defects noted in
animal studies and retrospective human case reports.
However, the relevance of animal data to human
pregnancies is unclear as only around 30 of the
approximately 1200 animal teratogens are teratogenic
in humans [36], and unsystematic, retrospective reports
are not adequate to provide a meaningful measure of risk.
Our systematic review of the available evidence to date
found no increased risk of overall birth defects among
women exposed to efavirenz during the ﬁrst trimester of
pregnancy compared with exposure to other antiretro-
viral drugs. The incidence of overall birth defects with
ﬁrst trimester efavirenz use (2.9%) was similar to the
ranges reported in the general population; 2.7% in the
United States [37], 2–5% in France [38], and 2.5–8% in
South Africa [39]. Only one case of a neural tube defect
was reported across all cohorts reporting congenital birth
defects among ﬁrst-trimester exposed women (1256
women with live births), giving a point prevalence
(0.08%) that is within the range reported among the
general population in the United Kingdom (0.14%) [40]
and South Africa (0.36%) [41]. Although these data
shouldprovidereassurancetohealthprovidersconfronted
with women who become pregnant while on efavirenz,
the low incidence of neural tube defects in the general
populationmeansthatalargersamplesizeisstillneededto
be able to deﬁnitively rule out an increased risk of this
speciﬁc defect. The range in prevalence of secondary
outcomes is an effect of both variability in the sample size
of individual studies and the diversity of settings included
in the review, resulting in differing background rates of
these outcomes in the general population. Pooled
estimates are not provided for secondary outcomes for
this reason.
Strengths of this review include a broad search strategy
thatidentiﬁedanumberofstudiesnotyetpublishedinthe
literature and the inclusion of updated data for several
cohorts. In addition, our primary analysis was limited to
datathatwerederivedfromprospectivestudies,whichare
less subject to reporting bias than retrospective reports.
Nevertheless, there may be a publication bias towards
reporting birth defects when awomen is on efavirenz and
but not reporting birth outcomes if no birth defects
occur. Such a publication bias would be expected to lead
to an overestimation of the risk of efavirenz compared
with other antiretroviral drugs.
An important limitation is that few studies reported on
risk of bias or attempted to control for potential
confounders, and we were therefore not able to assess
the potential effect of these in this review. In particular,
women on efavirenz may differ from those not on
efavirenz; the latter group may comprise more women
who planned their pregnancies and so were more likely
to be exposed to protective factors (such as folate
supplementation) and reduced risk factors (such as
smoking and poor diet). Consideration of confounding
is all the more important given that it would not be
ethicallyacceptabletoconductarandomizedtrialtoassess
risk. Nevertheless, such differences are unlikely to affect
our results importantly, and moreover would be expected
to result in an overestimation of the relative risk of birth
defects in the efavirenz group.
The main limitation to this review is the limited sample
size. Despite calls for more systematic recording of birth
outcomes from women receiving antiretroviral drugs
during pregnancy [42], such data remains persistently
under-reported, and while there has been a rapid increase
in women of childbearing age receiving efavirenz in
Africa in recent years, we were only able to identify one
registry report from Africa. The few prospective cohorts
that do provide reports are inconsistent in reporting of
birth outcomes beyond overall birth defects.
Our review provides several directions for research and
practice. First, the establishment of prospective birth
registries should be supported, particularly in African
countries where the majority of ﬁrst-trimester exposures
occur. A number of treatment cohorts contacted during
the conduct of this review stated that ﬁrst-trimester
efavirenz exposures were not uncommon, but that such
data were not routinely captured. This represents an
important missed opportunity. Second, there is a need to
support the standardized collection of birth outcome data
such that meaningful comparisons can be made with
respect not only to rates of birth defects but also other
important outcomes such as termination of pregnancy
and spontaneous abortions, stillbirths, and preterm
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deliveries. Third, women in childbearing age represent a
substantial proportion of the total number of people
infected with HIV in developing countries [43], and
healthcare providers will continue to be faced with
women presenting with unintended pregnancies while
taking efavirenz. The high rate of termination of
pregnancy reported in some cohorts points to a need
for improved counseling for women inadvertently
exposed during pregnancy. Fourth, periconceptional
provision of high-dose folates have proven efﬁcacy in
preventing neural tube defects among women with prior
risk and could be considered for women of childbearing
age who are receiving efavirenz and are likely to become
pregnant in settings where folate supplementation is
not provided [44]. Finally, efforts must continue to
support HIV-positive women to seek care early in their
pregnancy.
The potential risks of efavirenz in the ﬁrst trimester need
to be better quantiﬁed for healthcare providers,
particularly in Africa, where women will continue to
be exposed to efavirenz. Given an underlying incidence
of neural tube defects in the general population of 0.1–
0.4%, even a ﬁve-fold increase in risk would give an
overall incidence of less than 1%. Valproic acid, an
established human teratogen, is associated with a 10-fold
increase in the risk of neural tube defects, with an
incidence of neural tube defects in 1–2% of infants with
ﬁrst trimester exposures to the drug [45]. Such a level of
risk can be ruled out on the basis of available cohort data
for ﬁrst trimester efavirenz exposure presented in this
study. Finally, it is important to note that the neural tube
closes by around day 28 of gestation, therefore use of
efavirenz after this period should not be associated with a
risk for neural tube defect.
As with use of any drug in pregnancy, the beneﬁts of the
drug need to be weighed against the potential risk. The
balance of risks and beneﬁts of efavirenz in pregnancy
meritssomerecalibration,particularlyinresource-limited
settings where drug formularies are limited, women of
childbearing age represent the majority of those infected
with HIV, coinfection with tuberculosis is frequent, and
the risk of mortality in those who are eligible for ART
(CD4 cell count <350cells/ml or advanced clinical
disease) is high. It is also critical that as efavirenz use
increases among women in these countries that support is
given to establish adequate pharmacovigilance systems to
better deﬁne the risk.
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